drugset / Trial / NCT00492167
Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma
Phase 1
Completed
45 enrolled
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Beta-glucan may stimulate the immune system and stop tumor cells from growing. Monoclonal antibodies, such as 3F8, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving beta-glucan together with monoclonal antibody 3F8 may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of beta-glucan when given together with monoclonal antibody 3F8 in treating patients with metastatic neuroblastoma.
Timeline
- Start
- 2005-09-09
- Primary completion
- 2022-03-04
- Completion
- 2022-03-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 3F8 | Monoclonal antibody | 10 mg/m2 | Intravenous |
| Subject | beta-glucan | Other / unclassified | 10 mg/kg | Oral |
| Subject | beta-glucan | Other / unclassified | 120 mg/kg | Oral |
| Subject | beta-glucan | Other / unclassified | 200 mg/kg | Oral |